CalciMedica Inc. (NASDAQ: CALC) shares fell 2.1% on Tuesday, trading down to a session low of $5.55 before recovering slightly to $5.73 by the close. Total volume reached 44,801 shares, a 51% drop from the 92,307‐share average. This trading pattern follows a prior close of $5.85 and underscores a short‐term pullback in investor interest despite limited news catalysts.

Weiss Ratings reaffirmed a “sell (d‐)” rating on CALC shares on October 8th. On Wall Street, one analyst maintains a Buy recommendation and one Analyst has assigned a Sell rating, resulting in a consensus Hold rating. Based on data from MarketBeat.com, the average 12‐month price target stands at $16.00, indicating substantial upside from current levels if clinical and financial milestones are achieved.

As of the latest filings, CalciMedica carries a debt‐to‐equity ratio of 1.39, a quick ratio of 4.04 and a current ratio of 4.03, reflecting a strong liquidity position. The company’s market capitalization is $82.6 million, with a negative price‐to‐earnings ratio of 3.54 due to ongoing R&D expenses. Share volatility has been modest, with a beta of 0.58. Technical indicators include a 50‐day simple moving average of $4.12 and a 200‐day average of $3.24.

In its Q3 report on November 12th, CalciMedica posted a net loss of $0.39 per share, beating the consensus estimate of -$0.41 by $0.02. Sell‐side analysts forecast a full‐year EPS of -2.21. Institutional investors have shown renewed interest: Stonehage Fleming opened a $165,000 stake, Meritage Portfolio Management boosted its holding by 33.8% to 61,539 shares (valued at $189,000), Sheets Smith Investment Management initiated a $157,000 position, Cetera Investment Advisers added 9,045 shares for a 33.1% increase, and Sound View Wealth Advisors took a new $32,000 position.